In 2026, the biopharmaceutical sector is witnessing a paradigm shift as Organoids Market Data provides irrefutable evidence of the technology's impact on oncology drug discovery success rates. Recent clinical benchmarks indicate that drugs screened through patient-derived organoid (PDO) platforms demonstrate a 30% higher success rate in Phase I trials compared to those validated solely through...